Huang, T.-H.; Wei, S.-H.; Kuo, H.-I.; Hou, H.-Y.; Kuo, C.-W.; Tseng, Y.-L.; Lin, S.-H.; Wu, C.-L.
Baseline Blood Levels of Mucin-1 Are Associated with Crucial On-Treatment Adverse Outcomes in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Pirfenidone. Biomedicines 2024, 12, 402.
https://doi.org/10.3390/biomedicines12020402
AMA Style
Huang T-H, Wei S-H, Kuo H-I, Hou H-Y, Kuo C-W, Tseng Y-L, Lin S-H, Wu C-L.
Baseline Blood Levels of Mucin-1 Are Associated with Crucial On-Treatment Adverse Outcomes in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Pirfenidone. Biomedicines. 2024; 12(2):402.
https://doi.org/10.3390/biomedicines12020402
Chicago/Turabian Style
Huang, Tang-Hsiu, Sheng-Huan Wei, Hung-I Kuo, Hsin-Yu Hou, Chin-Wei Kuo, Yau-Lin Tseng, Sheng-Hsiang Lin, and Chao-Liang Wu.
2024. "Baseline Blood Levels of Mucin-1 Are Associated with Crucial On-Treatment Adverse Outcomes in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Pirfenidone" Biomedicines 12, no. 2: 402.
https://doi.org/10.3390/biomedicines12020402
APA Style
Huang, T. -H., Wei, S. -H., Kuo, H. -I., Hou, H. -Y., Kuo, C. -W., Tseng, Y. -L., Lin, S. -H., & Wu, C. -L.
(2024). Baseline Blood Levels of Mucin-1 Are Associated with Crucial On-Treatment Adverse Outcomes in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Pirfenidone. Biomedicines, 12(2), 402.
https://doi.org/10.3390/biomedicines12020402